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Abstract
Objectives: Urokinase-type plasminogen activator receptor is a multifunctional glycoprotein, the expression of which is
increased during inflammation. It is known to bind to b3-integrins, which are elementary for the cellular entry of
hantaviruses. Plasma soluble form of the receptor (suPAR) levels were evaluated as a predictor of severe Puumala hantavirus
(PUUV) infection and as a possible factor involved in the pathogenesis of the disease.
Design: A single-centre prospective cohort study.
Subjects and Methods: Plasma suPAR levels were measured twice during the acute phase and once during the
convalescence in 97 patients with serologically confirmed acute PUUV infection using a commercial enzyme-linked
immunosorbent assay (ELISA).
Results: The plasma suPAR levels were significantly higher during the acute phase compared to the control values after the
hospitalization (median 8.7 ng/ml, range 4.0–18.2 ng/ml vs. median 4.7 ng/ml, range 2.4–12.2 ng/ml, P,0.001). The
maximum suPAR levels correlated with several variables reflecting the severity of the disease. There was a positive
correlation with maximum leukocyte count (r = 0.475, p,0.001), maximum plasma creatinine concentration (r = 0.378,
p,0.001), change in weight during the hospitalization (r = 0.406, p,0.001) and the length of hospitalization (r = 0.325,
p = 0.001), and an inverse correlation with minimum platelet count (r =20.325, p = 0.001) and minimum hematocrit
(r =20.369, p,0.001).
Conclusion: Plasma suPAR values are markedly increased during acute PUUV infection and associate with the severity of the
disease. The overexpression of suPAR possibly activates b3-integrin in PUUV infection, and thus might be involved in the
pathogenesis of the disease.
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Introduction
Hantaviruses cause two clinical syndromes in humans, hemor-
rhagic fever with renal syndrome (HFRS) in Eurasia and
hantavirus cardiopulmonary syndrome (HCPS) in the Americas
[1,2]. Puumala hantavirus (PUUV), carried by the bank vole,
causes a mild HFRS called nephropathia epidemica (NE) [1,2].
NE is prevalent in Finland, elsewhere in Scandinavia, European
Russia, and many parts of Central-Western Europe [1,2]. In
Europe, PUUV causes most HFRS cases, and in Finland, 1,000–
3,000 serological PUUV infection diagnoses are made annually
(http://www3.ktl.fi) [3].
The clinical severity of NE varies from subclinical disease to
fatal cases. However, the mortality rate is low, about 0.1% [4].
Typical symptoms are sudden high fever, headache, abdominal
pain, nausea, backache, and visual disturbances, while serious
hemorrhagic manifestations are uncommon [5–8]. Signs of renal
involvement are proteinuria, hematuria, and oliguria, the latter
being followed by polyuria [5–8]. During the oliguric phase, about
5% of hospitalized patients need transiently hemodialysis treat-
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ment [6–8]. Usual laboratory findings are leukocytosis, thrombo-
cytopenia, anemia, elevation of plasma C-reactive protein (CRP)
and creatinine levels, as well as proteinuria and hematuria [6,7].
Radiological pulmonary manifestations have been detected in
about one-third of hospitalized patients [9,10].
The pathogenesis of NE is incompletely understood. An
important feature in hantavirus infections is universally increased
capillary permeability leading to vascular leakage, but the
mechanisms behind this phenomenon are unclear [11–13]. The
endothelium of the small vessels in various organs is the primary
target of hantavirus infection and b3-integrins mediate the cellular
entry of pathogenic hantaviruses [14,15]. It has been suggested
that immunological factors rather than direct cytotoxicity are
essential in the pathogenesis, since no obvious damage to the
endothelial cells is seen [11–13].
Several biomarkers have been shown to serve as indicators of
the severity of PUUV infection. The plasma levels of interleukin
(IL)-6, pentraxin-3 (PTX3), and indoleamine 2,3 dioxygenase
(IDO), all elements of the innate immunity, as well as of cellular
damage -reflecting cell-free DNA (cf-DNA) predict the outcome of
PUUV infection [16–19]. So does the urine levels of the
transcription factor necessary for the generation of type 2 T-cells,
GATA-3 [20]. On the contrary, although plasma CRP is elevated
in almost all of the patients with PUUV infection, high CRP level
does not indicate a more severe disease [19].
Urokinase-type plasminogen activator receptor (uPAR) is a
multifunctional glycoprotein, the expression of which is
increased during infection and inflammation [21,22]. It is
expressed on several different cell types, including monocytes,
activated T-lymphocytes, macrophages, neutrophils, endothelial
cells, and kidney podocytes [21,22]. uPAR interacts with several
molecules mediating immune system signals and promotes the
migration and adhesion of leukocytes by binding to b-integrins
[21,22]. Cell-cell contact has been shown to enhance the release
of the soluble form of the receptor (suPAR) by endothelial cells,
indicating a regulatory role of suPAR in cell adhesion [23]. The
levels of plasma suPAR are considered to represent the degree of
immunoactivation [22]. Plasma suPAR has been found to be
increased as well as predict disease severity in various
conditions, e.g. autoimmune diseases, cancer, malaria, tubercu-
losis, sepsis, and human immunodeficiency virus (HIV) infection
[22,24–30].
In the present study, our aim was to evaluate the association of
suPAR with the severity of acute PUUV infection and also assess
the possible role of suPAR in the pathogenesis of the disease.
Materials and Methods
Ethics statement
All subjects gave a written informed consent before participa-
tion and the study was conducted according to the principles
expressed in the Declaration of Helsinki and approved by the
Ethics Committee of Tampere University Hospital.
Patients
The study cohort consisted of 97 prospectively collected adult
patients with acute NE. The diagnosis of acute PUUV infection
was serologically confirmed in all cases [31]. The patients were
treated at the Tampere University Hospital (Tampere, Finland)
from November 2001 to February 2009. The median patient age
was 41 (range 22–77) years, and 63 (65%) were males. Part of the
patients (10–83 patients of the present cohort depending on the
previous study) has participated also in our previous studies [16–
20,32–35]. All the patients treated during November 2001 and
February 2009 were included in the study, if there was plasma left
for the analyses of suPAR concentration.
Study protocol
All 97 patients were examined during the acute phase of NE. A
detailed past and current medical history was obtained, and a
careful physical examination was performed. Blood samples were
collected between 7:30–9:30 in the morning for two consecutive
weekdays after hospitalization for the analysis of plasma suPAR.
Blood samples for the determination of plasma cf-DNA, PTX3,
IL-6, CRP, creatinine, and serum kynurenine (Kyn) and
tryptophan (Trp) levels, as well as the blood cell counts were
collected for up to five consecutive days. Other blood samples were
taken according to the clinical needs of the patient.
The highest and the lowest values of the various variables
measured during hospitalization for each patient were designated
as the maximum and minimum values.
Eighty-four (87%) of the 97 patients were also studied at the out-
patient clinic 1–4 weeks after the hospital period. The plasma
samples taken at the out-patient clinic after the hospital treatment
were regarded as control samples.
Methods
EDTA-treated plasma samples for suPAR determination were
collected from patients during hospitalization and at the out-
patient clinic and stored at 270uC until required for analysis.
Plasma suPAR levels were determined using a commercial
enzyme-linked immunosorbent assay (ELISA) (suPARnosticH
Standard kit;ViroGates A/S, Birkerød, Denmark) according to
the manufacturer’s instructions.
Plasma CRP and creatinine levels were analyzed using Cobas
Integra analyzer (F. Hoffman-La Roche Ltd, Basel, Switzerland).
Blood cell count was completed by hematological cell counters by
Bayer. Plasma IL-6 concentrations were determined as previously
described [36]. IDO level can be measured by determining the
ratio of Kyn to Trp in serum [37] by reverse-phase high
performance liquid chromatography (HPLC) as previously
described [38]. The Kyn/Trp ratio was calculated by relating
concentrations of Kyn to Trp. Plasma PTX3 determinations were
performed by using a commercially available human pentraxin-3
immunoassay (Quantikine, R&D Systems, Inc., Minneapolis,
MN), following the manufacturer’s instructions. Plasma cf-DNA
levels were determined as previously described [16]. Plasma IL-6,
PTX3, and cf-DNA, as well as serum Kyn and Trp concentrations
were measured afterwards from frozen samples.
Statistical Analyses
In order to describe the data, medians and ranges were given for
continuous variables and numbers and percentages for categorical
variables. Groups were compared using the Mann-Whitney U-
test. Correlations were calculated by the Spearman’s rank
correlation test. Wilcoxon’s test was used to compare two related
samples. All tests were two-sided, and statistically significant P-
values are given. All analyses were made with the SPSS (version
20) statistical software package (IBM, Chicago, IL).
Results
The clinical characteristics of the patients are shown in Table 1
and the laboratory variables measured during hospitalization in
Table 2. None of the patients was in clinical shock at the time of
admission and five patients (5%) needed hemodialysis treatment
during the hospital stay. No deaths occurred.
suPAR in Hantavirus Infection
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The maximum plasma suPAR levels taken during acute NE
were significantly elevated compared to the control values taken
after the hospitalization period (median 8.7 ng/ml, range 4.0–
18.2 ng/ml vs. median 4.7 ng/ml, range 2.4–12.2 ng/ml,
P,0.001). The control values were taken median 22 (range 15–
41) days after the onset of fever. Figure 1 shows the suPAR levels
in relation to the duration of the disease, i.e. the onset of fever.
The maximum plasma suPAR levels correlated with several
parameters reflecting the severity of acute PUUV infection
(Table 3). There was a positive correlation of suPAR with the
length of hospital stay and with the change in weight during
hospitalization, which reflects fluid retention during the oliguric
phase. Plasma suPAR also correlated positively with plasma
creatinine, CRP, PTX3, IL-6, IDO, and cf-DNA levels, as well as
with the blood leukocyte counts. An inverse correlation was
detected between maximum plasma suPAR level and minimum
urinary output as well as between maximum suPAR and minimum
platelet levels. There was no correlation between maximum
suPAR and age (Table 3).
The maximum suPAR level was higher in patients who required
dialysis treatment during hospitalization compared to patients who
managed without dialysis (Table 4). Patients who stayed longest
(.6 days) at the hospital had also higher suPAR levels than
patients with shorter hospitalizations. Furthermore, patients with
maximum creatinine level .200 mmol/l or maximum blood
leukocyte count .106109/l had higher suPAR levels compared to
patients with lower creatinine or leukocyte values. Significant
thrombocytopenia (platelet count ,506109/l) associated also with
higher suPAR levels. There was no difference in suPAR levels
between men and women (Table 4).
Discussion
In the present study, plasma suPAR levels in a hantavirus
infection are reported to our knowledge for the first time. The data
presented here show that plasma suPAR levels are clearly elevated
during acute PUUV infection. The suPAR values measured
during the acute phase were markedly higher than the control
values measured after the hospitalization and correspond with the
levels previously reported in bacteremic patients [25]. Further-
more, the convalescence phase levels correspond to the levels
previously measured in the general population [39]. The
maximum plasma suPAR levels also correlated with several
PUUV infection severity reflecting variables in the present study.
suPAR correlated positively with the length of hospital stay, the
change in body weight during hospitalization, plasma creatinine,
and the leukocyte counts. An inverse correlation was detected by
suPAR with minimum urinary output and minimum platelet
levels.
There was also a positive correlation between suPAR and the
biomarkers previously shown to predict the outcome of PUUV
infection, PTX3, IL-6, IDO, and cf-DNA [16–19]. PTX3, IL-6,
and IDO not only reflect the severity of PUUV induced NE, but
also the activation of the immune system, and are partly expressed
by the same type of cells as suPAR in response to inflammatory
signals. Furthermore, cf-DNA reflects the degree of cellular
damage. CRP, on the other hand, does not predict the outcome
of PUUV infection [19]. In the present study, however, suPAR
correlated also with CRP in PUUV-infected patients. This
probably is explained by CRP reflecting the activation of the
immune system, although it does not reflect the overall severity of
the disease in PUUV infection.
Systemic suPAR levels are considered to reflect the degree of
immunoactivation of the individual. This is corroborated by
numerous studies showing suPAR levels to be increased as well in
cancer as in various inflammatory and infectious diseases [22].
Furthermore, high suPAR concentrations are predictive of
outcome and mortality in these conditions [22]. Previous studies
on patients with infectious diseases have demonstrated that suPAR
can predict disease severity and case fatality in malaria,
tuberculosis, sepsis, bacterial meningitis, and some viral infections
[24–27,29,30,40–44].
Previously, suPAR has been studied only in a few viral
infections. However, in HIV infection, several studies show that
suPAR is a strong predictor of immunologic failure and mortality
[28,41]. In addition, the suPAR levels decrease with effective
antiretroviral therapy [40]. In patients with Crimean-Congo
hemorrhagic fever, suPAR is elevated and also predictive for
mortality [42]. Systemic suPAR levels also predict the progression
of liver fibrosis to cirrhosis in patients with chronic hepatitis C
[45,46]. Furthermore, elevated suPAR levels have been found in
the cerebrospinal fluid of patients with viral meningitis [44]. Here,
we demonstrate that suPAR is elevated and associates with severity
of the disease in PUUV-induced hantavirus infection.
The exact pathogenetic mechanisms in hantavirus infection are
currently still unclear. Pathological changes are marked by
increased capillary permeability in the affected organs, which also
explains many signs and symptoms in these infections [11–13].
Table 1. Clinical data of 97 patients with acute Puumala
hantavirus infection.
Median Range
Age (years) 41 22–77
Duration of fever before hospital
admission (days)
4 1–15
Total duration of fever (days) 7 2–19
Length of hospital stay (days) 6 2–15
Change in weight during
hospitalization (kg)
2.1 0–12.0
Minimum urinary output (ml/day) 1400 50–5800
doi:10.1371/journal.pone.0071335.t001
Table 2. Laboratory data of 97 patients with acute Puumala
hantavirus infection.
Median Range
suPAR max (ng/ml) 8.7 4.0–18.2
Creatinine max (mmol/l) 175 51–1499
Platelets min (109/l) 61 9–187
Hematocrit min 0.36 0.25–0.44
Leukocytes max (109/l) 10.4 3.9–31.2
CRP max (mg/l) 84.6 15.9–269.2
IL-6 max (pg/ml) (n = 29) 11.8 2.6–44.8
PTX3 max (ng/ml) (n = 42) 42.9 3.9–1085.5
IDO max (mmol/mmol) (n = 83) 202.2 47.7–3679.2
cf-DNA (mmol/ml) (n = 42) 1.35 1.04–3.29
Min =minimum, Max=maximum, suPAR= soluble urokinase-type plasminogen
activator receptor, CRP = plasma C-reactive protein, IL-6 = plasma interleukin-6,
PTX3 = plasma pentraxin-3, IDO= serum indoleamin 2,3-dioxygenase, cf-
DNA=plasma cell-free DNA.
doi:10.1371/journal.pone.0071335.t002
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The endothelium of the small vessels in various organs is the
primary target in hantavirus infection, and the cellular entry of
pathogenic hantaviruses is mediated by b3-integrins [11,13–15].
Integrins are heterodimeric surface receptors on endothelial cells
and platelets, mediating cell-to-cell adhesion, cell migration,
extracellular matrix protein recognition, and platelet aggregation.
b3-integrins have an important role in regulating vascular
integrity, endothelial cell permeability, and platelet functions
[47]. Pathogenic hantaviruses probably interfere with these
Figure 1. Line chart showing soluble urokinase-type plasminogen activator receptor (suPAR) maximum (median 8.7 ng/ml, range
4.0–18.2 ng/ml) and convalesce phase concentrations (median 4.7 ng/ml, range 2.4–12.2 ng/ml) in relation to the onset of fever
(day 0) in 97 patients with Puumala hantavirus infection (P-value for the difference ,0.001). Short title: Line chart showing suPAR
maximum and convalescence concentrations in relation to the onset of fever.
doi:10.1371/journal.pone.0071335.g001
Table 3. The correlations of maximum plasma suPAR levels
with clinical and laboratory variables reflecting the severity of
the infection in 97 patients with acute Puumala hantavirus
infection.
R P-value
Length of hospitalization 0.325 0.001
Change in weight during
hospitalization
0.406 ,0.001
Urinary output min 20.332 0.002
Creatinine max 0.378 ,0.001
Platelets min 20.325 0.001
Hematocrit min 20.369 ,0.001
Leukocytes max 0.475 ,0.001
CRP max 0.298 0.003
PTX3 max 0.425 0.005
IL-6 max 0.621 ,0.001
IDO max 0.557 ,0.001
cf-DNA max 0.363 0.018
Min =minimum, Max =maximum, CRP =C-reactive protein, PTX3 = pentraxin-3,
IL-6 = interleukin-6, IDO= indoleamine 2,3-dioxygenase, cf-DNA= cell-free DNA.
doi:10.1371/journal.pone.0071335.t003
Table 4. Maximum plasma suPAR levels in different patient
groups in 97 patients with Puumala virus infection.
suPAR levels
Median Range P-value
Sex 0.841
Male 8.6 4.2–18.2
Female 8.8 4.0–15.3
Dialysis 0.038
Yes 10.8 8.6–18.0
No 8.4 4.0–18.2
Hospital stay 0.007
.6 days 9.2 6.5–18.2
#6 days 8.3 4.0–13.1
Minimum platelet level 0.019
,506109/l 9.7 5.7–18.2
$506109/l 8.2 4.0–15.6
Maximum leukocyte
count
,0.001
.1069/l 9.2 5.7–18.2
#1069/l 7.5 4.0–13.1
Maximum creatinine 0.001
.200 mmol/l 9.4 6.5–18.2
#200 mmol/l 8.0 4.0–15.6
doi:10.1371/journal.pone.0071335.t004
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functions, hence increasing endothelial permeability [47]. uPAR,
in turn, interacts with integrins, including b3–integrins, and is
believed to regulate their activation degree by altering their
adhesive properties and signaling capacity [21,22].
In this study, we found that plasma suPAR is markedly elevated
in patients with PUUV-infection. Moreover, the higher the suPAR
level is, the severer is also the disease. Taken into account the role
of b3-integrins in the course of hantavirus infection, and on the
other hand, the interactions of (s)uPAR and integrins, our finding
presents as interesting. It brings up the possibility that increased
suPAR is involved in the pathogenesis of PUUV infection by
activating b3-integrins.
Conclusions
The plasma level of suPAR is elevated in acute PUUV
infection and associates with the severity of the disease.
Therefore, plasma suPAR determinations may offer a potential
diagnostic tool for assessing the severity and outcome of the
disease. In addition, it is possible that circulating suPAR is
involved in the pathogenesis of PUUV-induced hantavirus
infection by activating b3-integrins. However, future studies are
warranted to verify this assumption.
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